Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma After CAR T-Cell Therapy
NCT07003295Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Started Jul 2026; status: recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07003295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003295.